Published by Global Banking & Finance Review®
Posted on August 5, 2025
2 min readLast updated: January 22, 2026
Gland Pharma's Q1 profit surged by nearly 50%, driven by European sales growth and Cenexi's recovery, despite US market challenges.
(Reuters) -India's Gland Pharma reported a nearly 50% jump in first-quarter profit on Tuesday, driven by better margins and a recovery at its European unit Cenexi.
The company reported a consolidated net profit of 2.15 billion rupees ($24.50 million) for the quarter ended June 30, from 1.44 billion rupees in the year-ago quarter.
Revenue from operations rose 7.4% to 15.06 billion rupees. While sales from its U.S. business, which accounts for nearly half of the total, fell 2%, its Europe business posted a 29% rise.
For further results highlights, click [FWN3TX07W]
KEY CONTEXT
Gland and several Indian pharma companies that make generic drugs derive a significant share of revenue from the United States and has continued to face pricing pressure in that market following U.S. President Donald Trump's imposition of hefty tariffs on goods imported from India.
Rivals Sun Pharma and Cipla and Dr Reddy's reported subdued U.S. sales in the quarter.
However, Gland Pharma said improved margins and Cenexi's earnings before interest, taxes, depreciation, and amortisation (EBITDA) break-even supported quarterly performance, marking a turnaround after production setbacks at its Paris and Belgium units weighed on earnings over the past year.
The company’s EBITDA margin rose to 35% in the June quarter from 29% a year earlier.
PEER COMPARISON
Estimates (next Analysts' sentiment
12 months)
RIC PE EV/EBI Revenue Profit Mean # of Stock to Div
TDA growth growth rating* analysts price yield
(%) (%) target** (%)
Gland Pharma Ltd 32.17 17.87 12.86 31.29 Hold 11 1.18 0.91
Alembic 24.49 15.10 10.91 25.76 Buy 10 0.96 1.15
Pharmaceuticals
Ltd
Zydus Lifesciences 21.39 13.94 6.74 -5.10 Hold 26 0.96 1.16
Ltd
Cipla Ltd 23.92 15.31 6.65 -0.82 Buy 35 0.89 0.87
* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT
APRIL TO JUNE STOCK PERFORMANCE
-- All data from LSEG
-- $1 = 87.7570 Indian rupeesthe
(Reporting by Kashish Tandon in Bengaluru)
Gland Pharma reported a consolidated net profit of 2.15 billion rupees ($24.50 million) for the quarter ended June 30.
Gland Pharma's Europe business posted a 29% rise in sales, contributing significantly to the company's overall revenue growth.
The profit increase was driven by better margins and a recovery at its European unit, Cenexi, which achieved EBITDA break-even.
While Gland Pharma's U.S. business, which accounts for nearly half of its total revenue, fell by 2%, its Europe business experienced a significant increase.
Gland Pharma's EBITDA margin rose to 35% in the June quarter, up from 29% a year earlier.
Explore more articles in the Finance category
